Minimal invasive right ventricular and atrial pacemaker lead repositioning as a first alternative is superior in avoiding pocket complications with passive fixation leads

2017 ◽  
Vol 49 (1) ◽  
pp. 33-38 ◽  
Author(s):  
István Osztheimer ◽  
Szabolcs Szilágyi ◽  
Zsuzsanna Pongor ◽  
Endre Zima ◽  
Levente Molnár ◽  
...  
2014 ◽  
Vol 30 (6) ◽  
pp. 522-524
Author(s):  
Azeem S. Sheikh ◽  
Farazin Hosseini-Ardehali ◽  
Sajjad Mazhar

EP Europace ◽  
2009 ◽  
Vol 11 (7) ◽  
pp. 968-969 ◽  
Author(s):  
D. Tziakas ◽  
A. Alexoudis ◽  
F. Konstantinou ◽  
G. Chalikias ◽  
D. Stakos ◽  
...  

Author(s):  
Martin Riesenhuber ◽  
Andreas Spannbauer ◽  
Marianne Gwechenberger ◽  
Thomas Pezawas ◽  
Christoph Schukro ◽  
...  

Abstract Background Transcatheter tricuspid valve intervention became an option for pacemaker lead-associated tricuspid regurgitation. This study investigated the progression of tricuspid regurgitation (TR) in patients with or without pre-existing right ventricular dilatation (RVD) undergoing pacemaker implantation. Methods Patients were included if they had implantation of transtricuspid pacemaker lead and completed echocardiography before and after implantation. The cohort was divided in patients with and without RVD (cut-off basal RV diameter ≥ 42 mm). TR was graded in none/mild, moderate, and severe. Worsening of one grade was defined as progression. Survival analyses were plotted for 10 years. Results In total, 990 patients were analyzed (24.5% with RVD). Progression of TR occurred in 46.1% of patients with RVD and in 25.6% of patients without RVD (P < 0.001). Predictors for TR progression were RV dilatation (OR 2.04; 95% CI 1.27–3.29; P = 0.003), pre-existing TR (OR 4.30; 95% CI 2.51–7.38; P < 0.001), female sex (OR 1.68; 95% CI 1.16–2.43; P = 0.006), single RV lead (OR 1.67; 95% CI 1.09–2.56; P = 0.018), mitral regurgitation (OR 2.08; 95% CI 1.42–3.05; P < 0.001), and enlarged left atrium (OR 1.98; 95% CI 1.07–3.67; P = 0.03). Survival-predictors were pacemaker lead-associated TR (HR 1.38; 95% CI 1.04–1.84; P = 0.028), mitral regurgitation (HR 1.34; 95% CI 1.02–1.77; P = 0.034), heart failure (HR 1.75; 95% CI 1.31–2.33; P < 0.001), kidney disease (HR 1.62; 95% CI 1.25–2.11; P < 0.001), and age ≥ 80 years (HR 2.84; 95% CI 2.17–3.71; P < 0.001). Conclusions Patients with RVD receiving pacemaker suffered from increased TR progression, leading to decreased survival. Graphic abstract


EP Europace ◽  
2020 ◽  
Vol 22 (11) ◽  
pp. 1634-1634
Author(s):  
Juliana Elices-Teja ◽  
Olga Durán-Bobin ◽  
Carlos Gonzalez-Juanatey

Author(s):  
Hisashi Uemura ◽  
Shin Yajima ◽  
Naosumi Sekiya ◽  
Sachiko Yamazaki ◽  
Ayaka Satoh ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document